Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease

NCT00272181 is registered in ClinicalTrials.gov with Sesen Bio, Inc. as lead sponsor.

NCT NCT00272181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00272181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Lead sponsor
Sesen Bio, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2006
Completion date
October 31, 2007
Enrollment
15 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell, head and neck cancer, head and neck neoplasms, mouth neoplasms, neoplasms, squamous cell, squamous cell carcinoma of the head and neck